BUZZ-Retrophin Inc: U.S. senators probe drug pricing

Wed Nov 4, 2015 10:32am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]


** Drugmaker's shares down 16 pct at $18.23

** Two U.S. senators launched a bipartisan investigation into pharmaceutical drug pricing on Wednesday, requesting documents from four drugmakers, including Retrophin and Valeant Pharmaceuticals International Inc

** Valeant's U.S.-listed shares down about 1.1 pct at $96.82

** The other companies being investigated are privately held Turing Pharmaceuticals and Rodelis Therapeutics

** Shares of many drugmakers have slumped since Democratic presidential hopeful Hillary Clinton last month proposed ways to prevent industry "profiteering.

** Up to Tuesday's close, Retrophin's stock had fallen about 24 pct since Sept. 21 when Clinton tweeted her intent to tackle unnecessarily high prices in some drug markets